secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009489
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics reports FY 2022 net product sales up 25% to $107.7M; net loss narrows to $182M from $220.7M
--------------------------------------------------------------------------------

- Annual net product sales $107.7M (+25% YoY); Q4 net product sales $30.0M (+45% YoY).
- Net loss for FY 2022: $182.0M ($1.67/share) vs $220.7M ($2.24) in 2021; Q4 net loss $19.9M ($0.17).
- ZYNRELEF Q4 net sales $3.9M (+44% QoQ); APONVIE launched March 6, 2023 with CMS pass-through status.
- Oncology care franchise net sales $97.5M in 2022 (+17% YoY); FY 2023 guidance $99M-$103M.
- Cash and investments $84.9M at Dec 31, 2022, down from $157.6M; operating cash used $146.9M in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/0000950170-23-009489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023009489/hrtx-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer